[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338955-105":59,"doc-detail-338955-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genetics-and-beyond-precision-medicine-real-world-data-for-patients-with-cervical-vaginal-or-vulvar-cancer-in-a-tertiary-cancer-center","Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center","","Molecular tumor diagnostics have reshaped cancer care, yet the extent of their transformative impact across malignancies remains uncertain. This retrospective study analyzed HPV-related gynecologic cancer patients treated at an interdisciplinary Molecular Tumor Board (MTB) in a tertiary center between 11/2017 and 06/2022. Among 31 patients (cervical, vaginal, or vulvar), 22 carried at least one mutation, 15 showed actionable alterations, and 14 received MTB-targeted recommendations. Adherence barriers included patient refusal, rapid deterioration, stable disease, and biomarker-agnostic alternatives, leaving biomarker-guided implementation low and timely access challenging.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genetics-and-beyond-precision-medicine-real-world-data-for-patients-with-cervical-vaginal-or-vulvar-cancer-in-a-tertiary-cancer-center/338955/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genetics-and-beyond-precision-medicine-real-world-data-for-patients-with-cervical-vaginal-or-vulvar-cancer-in-a-tertiary-cancer-center/338955.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient cohort was analyzed in the study?","Question",{"text":112,"@type":113},"The study retrospectively analyzed 31 patients with HPV-related gynecologic malignancies who underwent comprehensive molecular profiling and discussion at the Molecular Tumor Board between 11/2017 and 06/2022.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients had actionable mutations or MTB recommendations?",{"text":117,"@type":113},"Twenty-two patients harbored at least one mutation, 15 had an actionable mutation, and 14 received an MTB recommendation for a targeted treatment.",{"name":119,"@type":110,"acceptedAnswer":120},"Why were some MTB recommendations not followed?",{"text":121,"@type":113},"Non-adherence was linked to informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody–drug conjugates or checkpoint inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338955,1791248807,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Article  \nGenetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center  \nFabian B. T. Kraus 1,2, *, Elena Sultova 1, Kathrin Heinrich 3, Andreas Jung 4,5, C. Benedikt Westphalen 3,5, Christina V. Tauber 1, Jörg Kumbrink 4,5, Martina Rudelius 4,5, Frederick Klauschen 4,5, Philipp A. Greif 3,5,6, Alexander König 1, Anca Chelariu-Raicu 1, Bastian Czogalla 1, Alexander Burges 1, Sven Mahner 1,  \nRachel Wuerstlein 1,† and Fabian Trillsch 1,†  \nCitation: Kraus, F.B.T.; Sultova, E.; Heinrich, K.; Jung, A.; Westphalen, C.B.; Tauber, C.V.; Kumbrink, J.; Rudelius, M.; Klauschen, F.; Greif, P.A.; et al. Genetics and beyond:  \nPrecision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center. Int. J. Mol. Sci. 2024, 25, 2345 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25042345  \nAcademic Editor: Apostolos Zaravinos  \nReceived: 14 January 2024  \nRevised: 9 February 2024  \nAccepted: 9 February 2024  \nPublished: 16 February 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany  \n2 Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA  \n3 Department of Medicine III, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany  \n4 Institute of Pathology, Comprehensive Cancer Center Munich, LMU University Hospital, Ludwig Maximilians University (LMU), 81377 Munich, Germany  \n5 German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany  \n6 German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany  \n* Correspondence: [fabian.kraus@med.uni-muenchen.de](fabian.kraus@med.uni-muenchen.de)[ ](fabian.kraus@med.uni-muenchen.de)† These authors contributed equally to this work.  \nAbstract: Advances in molecular tumor diagnostics have transformed cancer care. However, it remains unclear whether precision oncology has the same impact and transformative nature across all malignancies. We conducted a retrospective analysis of patients with human papillomavirus (HPV)-related gynecologic malignancies who underwent comprehensive molecular profiling and subsequent discussion at the interdisciplinary Molecular Tumor Board (MTB) of the University Hospital, LMU Munich, between 11/2017 and 06/2022 . We identified a total cohort of 31 patients diagnosed with cervical (CC), vaginal or vulvar cancer. Twenty-two patients (fraction: 0.71) harbored at least one mutation. Fifteen patients (0.48) had an actionable mutation and fourteen (0.45) received a recommendation for a targeted treatment within the MTB. One CC patient received a biomarkerguided treatment recommended by the MTB and achieved stable disease on the mTOR inhibitor temsirolimus for eight months. Factors leading to non-adherence to MTB recommendations in other patient cases included informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody–drug conjugates or checkpoint inhibitors. Despite a remarkable rate of actionable mutations in HPV-related gynecologic malignancies at our institution, immediate implementation of biomarker-guided targeted treatment recommendations remained low, and access to targeted treatment options after MTB discussion remained a major challenge.  \nKeywords: molecular tumor board; precision medicine; human papillomavirus; targeted therapies; antibody–drug conjugates; checkpoint inhib","cbCaijgwHoJEtS9G","https://ap.wps.com/l/cbCaijgwHoJEtS9G","pdf",3502275,17,"English","# Abstract\n# Introduction\n## HPV and cervical cancer burden\n## Risk factors and oncogenic mechanisms\n## Progression to neoplasia and invasive disease\n## Role in vulvar and vaginal lesions","[{\"question\":\"What patient cohort was analyzed in the study?\",\"answer\":\"The study retrospectively analyzed 31 patients with HPV-related gynecologic malignancies who underwent comprehensive molecular profiling and discussion at the Molecular Tumor Board between 11/2017 and 06/2022.\"},{\"question\":\"How many patients had actionable mutations or MTB recommendations?\",\"answer\":\"Twenty-two patients harbored at least one mutation, 15 had an actionable mutation, and 14 received an MTB recommendation for a targeted treatment.\"},{\"question\":\"Why were some MTB recommendations not followed?\",\"answer\":\"Non-adherence was linked to informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody–drug conjugates or checkpoint inhibitors.\"}]","Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center | PDF",1790026766,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8398250d61041e713247cf32dcd4779a.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1e21d9ea20690ce23dc01f894286e30.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d96c5b0032331b956d5da99b091ca874.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b5bcc48e6978af8166ef62eb7256cd8.webp",980,1385]